ASP546C
Antibody–drug conjugate
Also known as XNW27011, XNW270115
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Gastric Cancer
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06792435 NCT06792435 · Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic, Biliary Tract Cancer, Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma Registry: NCT06792435 | 1/2 | Phase I (Dose Escalation):To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of XNW27011 (Baseline up to approximately 2 years); Phase Ⅱ (Dose Expansion):To evaluate the objective response rate (ORR) of XNW27011 by cohorts at RP2D. The objective response includes the complete response (CR) and the partial response (PR). (Baseline up to approximately 2 years) 2026-12-30 | In progress: results expected 30 Dec 2026 | not yet graded | link ↗ |
View 1 more trial
NCT07488676 NCT07488676 · Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma Registry: NCT07488676 | 1/2 | Part 1: Objective Response Rate (ORR) per Investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to 36 Months); Part 1: Pharmacokinetics (PK) of ASP546C Antibody-drug Conjugate (ADC): Serum Concentrations of Antibody-drug Conjugate (Up to 39 Months); Part 1: PK of ASP546C ADC: Maximum Concentration (Cmax) (Up to 39 Months); Part 1: PK of ASP546C ADC: Area Under the Serum Concentration-time Curve from Time Zero to 21Days (AUC0-21d) (Up to 39 Months); Part 1: Number of participants with Adverse events (AEs) (Up to 39 Months); Part 1: Number of Participants with Vital Sign Abnormalities and/or AEs (Up to 39 Months); Part 1: Number of Participants with Laboratory Value Abnormalities and/or AEs (Up to 39 Months); Part 1: Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status Scores (Up to 39 Months) 2029-07-31 | In progress: results expected 31 Jul 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other Claudin 18.2 (CLDN18.2) drugs
Sonesitatug vedotin, SHR-A1904. Compare all 3 Claudin 18.2 (CLDN18.2) drugs
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Gastric Cancer: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ASP546C: this drug | Stage not on record | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Reliable signal | NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4) NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7) | |
| Tislelizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| ASP2138 | Phase 3 | Multispecific antibody | Claudin 18.2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| ONO-4578 | Phase 3 | Small molecule | Prostaglandin E2 receptor 4 (EP4) | Reliable signal | NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040. | |
| Retlirafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 and TGF-beta (TGF-βRII trap) | Partial signal | NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24). | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Serplulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Sonesitatug Vedotin | Phase 3 | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| agenT-797 | Phase 2 | Cell therapy | Invariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigen | not yet graded | No reviewed efficacy summary in this indication | |
| Givastomig | Phase 2 | Multispecific antibody | Claudin 18.2 (CLDN18.2) x 4-1BB | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-A1904 | Phase 2 | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-921 | Phase 1/2 | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| Afivastobart | Phase 1 | Monoclonal antibody | CD39 (ENTPD1) | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ASP546C to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.